M108

M108 is a monoclonal antibody developed by FutureGen Biopharmaceutical (Beijing). Its target is Claudin 18.2 (the sponsor names Claudin 18.2 (CLDN18.2)). ClinicalTrials.gov describes the intervention as: M108 monoclonal antibody will be administered as a minimum 2-hour IV infusion. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06177041 (M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma), in gastric & gastro-oesophageal junction cancer. The largest, NCT06177041, plans to enrol 486 participants with primary completion expected 2027-01-11. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.